Navigation Links
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Date:4/3/2009

SAN FRANCISCO, April 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Market informing the Company that it does not currently comply with NASDAQ Marketplace Rule 4310(c)(3). NASDAQ Marketplace Rule 4310(c)(3) requires companies maintain either: (i) $2,500,000 in stockholders' equity; (ii) a market value of listed securities of $35,000,000; or (iii) net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years. The Company intends to submit a specific plan to achieve and sustain compliance with the $2,500,000 stockholders' equity standard by April 15, 2009, including the time frame for completion of the compliance plan. If the NASDAQ staff determines that the Company's plan does not adequately address the issue noted above, the NASDAQ staff will provide written notice that the Company's securities will be delisted. At that time, the Company may appeal the NASDAQ staff's determination to a NASDAQ Listing Qualifications Panel (the "Panel"), which would stay any further delisting action by NASDAQ pending a final decision by the Panel. No assurances can be provided that NASDAQ will grant the Company sufficient time to execute its plan to insure that it will maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
2. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
4. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
5. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
6. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
7. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
8. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
11. VIA Pharmaceuticals Complies With NASDAQ Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
(Date:3/3/2015)... SAN DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - ... company developing new therapeutics and molecular diagnostics that target ... for the quarter and seventh-month period ended December 31, ... changed its fiscal year end from May 31 to ... periods we are reporting today are for the quarter ...
(Date:3/3/2015)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... odour control projects in North America , the ... . "Bidding activity in 2015 continues to be robust" ... high volume year for bidding in 2014, we are pleased to ... orders reflect the organization,s renewed focus on select market segments where ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies announced ... is joining its Board of Director as Chair of ... at Zillow Group, Chad oversees all finance, treasury and ... the company,s core finance, treasury and accounting functions, and ... nine acquisitions. In 2013, he was named Puget Sound ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX) ("GeoVax" or ... diseases caused by HIV-1 (Human,Immunodeficiency Virus) and other ... results and provided an operational update., Robert ... very,pleased with the progress we,ve made during the ...
... results in,more favorable lipid profile in mixed ... Using the VAP Cholesterol,Test from Atherotech, ... of,Point Medical, Rond Point de la Nation, ... subclasses and LDL particle size using,combination therapy. ...
... November 10 In a,presentation yesterday at ... from deCODE genetics (Nasdaq: DCGN ) presented ... populations that,underscore the clinical utility of the ... treatment of atrial fibrillation as a means ...
Cached Biology Technology:GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 2GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 3GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 4GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 5GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 6GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 7GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 8GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update 9VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy 2VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy 3deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 2deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 3deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 4deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke 5
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:3/2/2015)... , March 2, 2015  Businesses have a ... protection company Tharon Rankins Enterprises has announced the ... an ultra-safe way for businesses to protect their ... transactions. Beconux is a biometric ... Enterprises. Functioning similarly to an ATM machine, the ...
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... the European Society for Clinical and Economic Aspects of ... international congress devoted to musculoskeletal research and clinical practice ... Key facts about the IOF-ESCEO World Congress on Osteoporosis, ... More than 5000 delegates from 100 countries and over ...
... University of Minnesota College of Veterinary Medicine (CVM) has ... asthma. ORMDL3, a gene recently linked to asthma susceptibility, ... recruit inflammatory cells during an airway allergic reaction. Study ... . U of M researchers including Srirama Rao, ...
... 2013 EcoHealth Alliance, a nonprofit organization that focuses on ... a three-year, $2 million award to address land use alteration ... change in Asia. The funding for the new program ... Mission for Asia (RDMA). Over 60 percent of emerging ...
Cached Biology News:World's largest event for bone, muscle, and joint research and practice to be held in Spain 2U of M research uncovers gene's contribution to asthma susceptibility 2EcoHealth Alliance announces new award from USAID to combat disease emergence and climate change 2
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: